|
Market Closed -
Nasdaq
01:30:00 22/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 834.04 USD | +0.90% |
|
+3.48% | +8.05% |
| 19/08 | Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition | MT |
| 19/08 | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 8.25TCr 7.07TCr 6.62TCr 6.06TCr 11TCr 7,89800Cr 12TCr 78TCr 30TCr 3,96700Cr 31TCr 30TCr 13,12300Cr | P/E 2026 * |
19.3x | P/E 2027 * | 16.6x |
|---|---|---|---|---|---|
| Enterprise Value | 7.57TCr 6.48TCr 6.07TCr 5.55TCr 10TCr 7,24100Cr 11TCr 72TCr 28TCr 3,63700Cr 28TCr 28TCr 12,03100Cr | EV / Sales 2026 * |
4.47x | EV / Sales 2027 * | 3.91x |
| Free-Float |
71.07% | Yield 2026 * |
0.47% | Yield 2027 * | 0.53% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.90% | ||
| 1 week | +3.48% | ||
| Current month | +9.36% | ||
| 1 month | +24.09% | ||
| 3 months | +28.36% | ||
| 6 months | +6.97% | ||
| Current year | +8.05% |
| 1 week | 795.73 |  | 847 |
| 1 month | 637.8 | | 847 |
| Current year | 591.52 | | 847 |
| 1 year | 541 | | 847 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/08/26 | Fiscal year | Director | 1,200 | 0.0012% | ||
| 10/08/26 | Fiscal year | Director | 2,400 | 0.0023% | ||
| 02/07/26 | Sell | Director | -200 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.90% | +3.48% | +41.12% | +2.66% | 8.25TCr | |
| -1.69% | +22.38% | -23.76% | -37.80% | 5.84TCr | |
| +8.86% | +128.01% | +439.72% | +42.82% | 5.32TCr | |
| -1.46% | -0.83% | -1.01% | +30.84% | 5.22TCr | |
| +1.74% | +1.19% | +13.58% | +175.40% | 4.85TCr | |
| +1.13% | +2.91% | +55.97% | -16.99% | 3.17TCr | |
| +0.46% | +6.05% | +48.27% | +99.58% | 2.58TCr | |
| +1.19% | +7.62% | +8.19% | +225.60% | 2.25TCr | |
| -5.74% | +0.79% | -1.19% | +842.24% | 1.7TCr | |
| -0.30% | +2.54% | +61.86% | +125.05% | 1.69TCr | |
| Average | -0.35% | +15.46% | +64.28% | +148.94% | 4.09TCr | |
| Weighted average by Cap. | -0.07% | +19.26% | +74.00% | +82.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.69TCr 1.45TCr 1.36TCr 1.24TCr 2.33TCr 1,61900Cr 2.36TCr 16TCr 6.25TCr 81TCr 6.35TCr 6.22TCr 2,69000Cr | 1.84TCr 1.58TCr 1.48TCr 1.35TCr 2.54TCr 1,76200Cr 2.57TCr 17TCr 6.8TCr 89TCr 6.92TCr 6.77TCr 2,92800Cr |
| Net income | 477.34Cr 408.89Cr 382.58Cr 350.21Cr 657.25Cr 46TCr 665.93Cr 4.52TCr 1.76TCr 23TCr 1.79TCr 1.75TCr 76TCr | 544.54Cr 466.45Cr 436.45Cr 399.52Cr 749.78Cr 52TCr 759.69Cr 5.16TCr 2.01TCr 26TCr 2.04TCr 2TCr 87TCr |
| Net Debt | -686.84Cr -588.34Cr -550.5Cr -503.92Cr -945.71Cr -66TCr -958.21Cr -6.5TCr -2.54TCr -33TCr -2.58TCr -2.52TCr -1,09200Cr | -1.06TCr -904.04Cr -845.89Cr -774.31Cr -1.45TCr -1,01000Cr -1.47TCr -9.99TCr -3.9TCr -51TCr -3.96TCr -3.88TCr -1,67800Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $834.04 | +0.90% | 7,71,319 |
| 20/26/20 | $826.64 | -1.69% | 5,96,474 |
| 19/26/19 | $840.84 | +3.78% | 7,50,445 |
| 18/26/18 | $810.24 | +0.53% | 7,79,072 |
| 17/26/17 | $805.93 | +0.30% | 5,41,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
